+91-80-26860424 / 34

Call Us Today

LinkedIn

 

Compulsory License Tag

BananaIP Counsels > Posts tagged "Compulsory License"

Free Masterclass on IP; Nokia and Daimler settle SEP patent dispute; EU submits alternative proposal to WTO against IP waiver and more

Weekly Patent News

In this week’s patent news - Want to know how to file a patent? or expedite the patent process? Join us this week; Nokia and Daimer settle SEP patent dispute, sign patent licensing agreement; EU submits alternative proposal to WTO against IP waiver; and USPTO announces change to its implementation of structured text filing. Want to know how to file a patent? or expedite the patent process? Join us this week BananaIP in association with Nasscom will be conducting the 3rd module of the free Masterclass on Intellectual Property, this week, on the 10th of June 2021. In this module, the speakers...

Continue reading

In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies

The featured image is a quote by John F. Kennedy which reads "There are risks and costs to action. But they are far less than the risks of comfortable inaction"

During the last two days, two interesting articles addressing accessibility of medical products and methods were published. While one article in 'The Hindu' spoke about capitalism and its inherent hurdles to access, another article written by Professor Arul Scaria in 'The Wire' argued against Niti Aayog's approach towards access to COVID vaccines and medicines. In his article, Professor Scaria specifically pointed out that Government's reluctance to use the compulsory licensing mechanism as a part of the COVID vaccine/medicine access scheme reflects a very poor policy choice, and is not in line with India's legal framework and access philosophy. At different...

Continue reading

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Weekly Patent News

In this week’s patent news: Patent Office notifies Supreme Court’s order on Extensions of Timelines; Patent office announces JPO/IPR Training Course FY 2021; BananaIP and NASSCOM to organize a Master Class on IP; Panacea Biotec accuses Sanofi of patent infringement, files suit; Natco and Eli Lilly sign patent license agreement for production of Barcitinib; NATCO and Eli Lilly sign patent license agreement for production of Barcitinib; India and South Africa propose three-year patent waiver. Patent Office notifies Supreme Court’s order on Extensions of Timelines The Indian Patent office has issued a public notice in furtherance of the Supreme Court’s order of 27th...

Continue reading

Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more

Weekly Patent News

In this week’s patent news: Natco files compulsory license request for Baricitinib; USA approves temporary patent waiver; EU critical of US proposal for patent waiver, calls for removal of export restrictions; Ericsson and Samsung settle latest patent dispute, sign global patent license agreement; WIPO publishes guide on “International Registration of Industrial Designs under the Hague Agreement” and USPTO hiring hundreds of new patent examiners.  Natco files compulsory license request for Baricitinib Hyderabad based generic drug manufacturer Natco Pharma Limited has a filed a request with the Controller of Patents seeking the grant of a compulsory license under Section 92(1) read with Section...

Continue reading

Delhi High Court asks government to consider issuing compulsory licenses, World IP day 2021, a solemn affair this year, India – South Africa patent waiver proposal opposed again and more

Weekly Patent News

In this week’s patent news and updates - World IP day 2021, a solemn affair this year; Calls for compulsory license on COVID vaccine grows stronger; Government should not hesitate in invoking compulsory licensing provisions says Delhi High Court; Intel wins patent trial involving VLSI Technology; India - South Africa patent waiver proposal opposed by EU, UK and Switzerland at WTOP TRIPS meet; Lawmakers and nonprofit groups urge Biden administration to back 'moral' patent waiver. Indian Patent Updates World IP day 2021, a solemn affair this year April 26th, celebrated as World IP day every year will be a solemn affair this year,...

Continue reading

CPI(M) asks Government to issue compulsory license for Remdesivir, EPO creates search strategies to help fight against COVID-19 and more patent news

In this week’s Patent News – CPI(M) asks Government to issue compulsory license for manufacturing generic versions of drug – Remdesivir; EPO creates search strategies to aid scientists distinguish documents relevant to fight the COVID-19 pandemic; EUIPO and EPO to jointly host online conference on Additive Manufacturing INDIA PATENT NEWS UPDATE CPI(M) asks Government to issue compulsory license for manufacturing generic versions of drug - Remdesivir The Communist Party of India (Marxist) has reportedly requested the Central Government to issue a compulsory license to manufactures for the production of generic versions of drug – Remdesivir. Remdesivir, originally an anti-viral, is now being used...

Continue reading

Compulsory Licensing in India – Talk by Gaurav Mishra

Mr. Gaurav Mishra, Managing Associate at BananaIP Counsels delivered a talk on the Compulsory licensing provisions in India under the Patents Act on the 3rd of June 2020 at an event organized by the Department of Science and technology, Rajasthan. The webinar event was attended by over a 100 participants including, students, lawyers, medical professionals and academicians.  The talk was delivered as part of the Rajasthan, DST's laudable initiative of creating IP awareness as well as helping the attendees grasp the nuances of the Indian Patent Law.  In this presentation, Mr. Gaurav covered topics such as Grounds for issue of compulsory...

Continue reading

Statement of Working to Compulsory Licensing – Are We Missing Something?

This post was first published on 8th April, 2011.   As pointed out by Supriya in her post, a compulsory license may be granted if a patent is not worked in India and reasonable efforts are made to acquire a license. Does the working of a patent in India mean that the patented invention must be manufactured in India? Reading of sections 83 and 84 of the Patents Act take us to that logical conclusion. The sections clearly point out that working of a patented invention in India through only importation would not be enough to avoid a compulsory license.  Form 27...

Continue reading

Compulsory License for “Not working”

Intellectual Property

This post was first posted on 8th April, 2011.   In a recent development, non-compliance with regard to the requirement of local working of patent, required under patent law, may lead to issue of compulsory licenses to generics for seven top selling drugs. The RTI query sought by SpicyIP (Way to go Spicy IP!) seeking information regarding Form 27 filings by Innovators for the top selling drugs Tarceva (Roche and OSI Pharms), Stutent (Pfizer), Nexavar (Bayer), Sprycel; Dasatinib (BMS), Pegasys (Roche), Viraferonpeg (Schering) and Baraclude;Entecavir (BMS) revealed non-compliance by the Innovators. Ideally, patent holders are required to furnish a statement regarding the working...

Continue reading

Lee and BDR decision – the End of Compulsory Licenses?!

The featured image shows the words thats all folks. this post is about the decision of two indian generic drug manufactures to drop their request for Compulsory licenses. to read more click here.

Earlier this week, the words, “Compulsory License”, “Section 84” and “Indian pharma” once again made the headlines. This time however, it wasn’t a new case being brought forth; instead it was the decision to bury two old ones. The news reports suggested that two Indian drugmakers had given up a battle to copy drugs developed by Bristol Myers Squibb and AstraZeneca, blaming a lack of government support for cheap generics and pressure from Big Pharma. The two Indian drug makers being mentioned here include, BDR Pharma and Lee Pharma. We at Sinapse have carried several posts on the issues of compulsory...

Continue reading
css.php